Value delivered

Biotech R&D is under intense pressure to move faster, compute more, and adapt constantly, without compromising security or scientific rigor. But outdated infrastructure, limited scalability, and unreliable workflows are major roadblocks for scientific and IT teams alike.
A leading biotech company recently faced this exact challenge. The organization leverages advanced computational biology techniques and AI/ML (Artificial Intelligence and Machine Learning) to develop therapies that target underlying disease causes. Their legacy systems and original IT vendor could no longer support the growing demands of their structural biology and machine learning teams, and their AI/ML collaboration with a top 10 pharma. Delays in data processing and infrastructure failures were holding back discovery and putting timelines at risk.
That changed when they partnered with Clovertex.
Clovertex delivered a tailored, cloud-native computational platform with robust High-Performance Computing (HPC) support, secure virtual desktops, and automated data workflows that cut cryoEM data transfer processing time by 30% and boosted computational workflow efficiency by 20%. Scientists now work with faster insights, facilitating their large pharma partnership; IT teams operate with greater stability; and, with an IT infrastructure management process that prioritizes continuous updates and modernization, the company is effectively positioned for long-term growth.
Whether you’re leading a drug discovery research program or responsible for the infrastructure behind it, modern, scalable scientific computing is no longer a luxury; it’s a necessity.
Want to see the full transformation?
Download the full case study to learn how Clovertex helped a top biotech overcome complexity and unleash innovation with elastic HPC, automated data workflows and cloud-native tools engineered for the next generation of life sciences research.
Go deeper
Originally published on clovertex.com on July 24, 2025.
